



April 1, 2020

Via E-mail: AGO.highcostprescriptiondrugs@vermont.gov

Subject: Amended Notice pursuant to 18 V.S.A. § 4637(b)

To the Office of the Attorney General of Vermont:

Glenmark Pharmaceuticals Inc., USA ("Glenmark") notified the Vermont Attorney General of the below new prescription drug pursuant to 18 V.S.A. § 4637(b) on January 21, 2020. This amended notice is to provide the revised Wholesaler Acquisition Cost effective April 1, 2020 for these drugs.

NDC Number	Product Description	Date of Commercial Availability	Wholesale Acquisition Cost (As of date of commercial availability)	Wholesale Acquisition Cost as of April 1, 2020
68462-0494-30	Deferasirox Tablets for Oral Suspension, 125 mg	January 17, 2020	\$ 675.89	\$ 190.03
68462-0495-30	Deferasirox Tablets for Oral Suspension, 250 mg	January 17, 2020	\$ 1,351.76	\$ 380.05
68462-0496-30	Deferasirox Tablets for Oral Suspension, 500 mg	January 17, 2020	\$ 2,703.46	\$ 760.08